Phaseline

Targets › CD8B

CD8B (T-cell surface glycoprotein CD8 beta chain): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. (UniProt, P10966)

Open in Phaseline: the race on CD8B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterZirconium Zr 89-Df-Crefmirlimab
Anti-CD8 positron emission tomography imaging agent
CD8A, CD8BPhase 1Metastatic Malignant Solid NeoplasmOct 2027

Conditions

Metastatic Malignant Solid Neoplasm (1)

Modalities

antibody (1)

Companies

City of Hope Medical Center (1)

Related targets

CD8A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.